Replies to post #167 on Equity Field Notes from temporal sources

[DanWebzster]

SNDX 's lead program is in a Ph3 study for a highly-difficult-to-treat breast cancer.

Entinostat's Ph3 results will be out Q-3/2018.

Entinostat is also being assessed in a combination with other flagship drugs.

Cash runway is only into H-1/2019.

This will become a struggling biotech if the Ph3 lung cancer results are weak.